## Vikash Dadlani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11788571/publications.pdf

Version: 2024-02-01

20 1,051 11 papers citations h-index

20 20 20 944 all docs docs citations times ranked citing authors

17

g-index

#	Article	IF	CITATIONS
1	Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 357-361.	4.4	7
2	Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. Diabetes Technology and Therapeutics, 2021, 23, 245-252.	4.4	13
3	Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 342-349.	4.4	58
4	Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. Diabetes Technology and Therapeutics, 2021, 23, 673-683.	4.4	30
5	Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System. Diabetes Technology and Therapeutics, 2021, 23, 791-798.	4.4	13
6	P.157: NK and B Cell Subset Assessment in Type I Diabetes Patients on Waitlist for Pancreas Transplantation. Transplantation, 2021, 105, S65-S65.	1.0	0
7	P.155: Altered T Cell Compartment in Type 1 Diabetes With End Stage Renal Disease. Transplantation, 2021, 105, S63-S64.	1.0	O
8	Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2020, 43, 1822-1828.	8.6	34
9	Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care, 2020, 43, 607-615.	8.6	40
10	Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 1707-1717.	27.0	643
11	Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation. Clinical Transplantation, 2019, 33, e13719.	1.6	11
12	Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes. Current Diabetes Reports, 2018, 18, 88.	4.2	26
13	Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. Diabetes Care, 2017, 40, 1719-1726.	8.6	68
14	High Glucose Variability in Hospitalized Patients with Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, 572-579.	4.4	4
15	Assessment of Interday Glucose Variability in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 443-445.	4.4	3
16	Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1954-1962.	3.6	24
17	Role of Automation/Technology in Day-to-Day Diabetes Care. Diabetes Technology and Therapeutics, 2016, 18, 273-275.	4.4	O
18	Continuous Glucose Monitor Use and Accuracy in Hospitalized Patients. Diabetes Technology and Therapeutics, 2016, 18, 449-451.	4.4	2

#	Article	IF	CITATIONS
19	Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3878-3886.	3.6	67
20	Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1208-1216.	2.2	8